Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Roflumilast Tablets, 250 mcg (USRLD: Daliresp Tablets, 250 mcg).
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD). It is used to prevent worsening of symptoms in people with severe COPD. The drug will be manufactured at the group’s formulation manufacturing facility in SEZ Ahmedabad, (India).
Roflumilast Tablets, 250 mcg had annual sales of USD 34 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 363 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Navi Mumbai Demolition Case: Bombay HC Seeks Report To Determine If Plea Qualifies As PIL
Mumbai Environment Alert: BMC To Enforce Stricter Pollution Penalties On Construction Sites From November
26/11 Mumbai Terror Attack Case: 'Won’t Pass Any Order On Fahim Ansari’s Police Clearance Without Granting Access To State Material,' Says Bombay HC
Mumbai Tragedy: 52-Year-Old Priest Dies By Suicide In Kandivali Temple After Complaint Of Sexual Misconduct; Probe Underway
